Immunology Trials: Innovation Brings Hope, Fresh Challenges
The cost of developing drugs continues to escalate. Estimates vary, but the Tufts Center for the Study of Drug Development estimated the out of pocket pre-tax costs to be $1.4 billion per approved new product in 2013 dollars. It is not unreasonable to assume that this has continued to rise over the intervening years. In view of these rising costs it is more crucial than ever before that Sponsor companies try to mitigate against failure and delay in their drug developments.
In this whitepaper, WCG explore aspects of immunology clinical trials that deserve particular focus in order to provide the greatest opportunity for success.